In 2015, the American Thyroid Association (ATA) guidelines for the first time endorsed active surveillance (AS) as an alternative to immediate surgery in select patients with low-risk papillary thyroid cancer (PTC).1 To date, very few patients in the US are being treated with AS. The numbers of newly diagnosed patients with PTC who may be AS candidates in the coming years are not known.